- Home
- ARVN vs VGM Comparison
ARVN vs VGM Comparison
Compare ARVN & VGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARVN | VGM |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 560.2M |
| IPO Year | 2018 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ARVN | VGM |
|---|---|---|
| Price | $8.27 | $9.65 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 711.6K | 139.5K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.97 | $9.55 |
| 52 Week High | $14.22 | $10.66 |
Technical Indicators
Market Signals| Indicator | ARVN | VGM |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 30.59 |
| Support Level | $7.90 | $9.57 |
| Resistance Level | $8.40 | $10.49 |
| Average True Range (ATR) | 0.32 | 0.13 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 11.88 | 11.24 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
About VGM Invesco Trust for Investment Grade Municipals (DE)
Invesco Trust for Investment Grade Municipals is active in the financial services sector. Its investment objective is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.